Hugh A. SampsonChief Scientific Officer and Interim Chief Medical Officer

    Hugh A. Sampson was appointed Chief Scientific Officer (CSO) in June 2015, interim Chief Medical Office (CMO) in January 2019 and is a member of the Company’s Scientific Advisory Board. Dr. Hugh Sampson is also the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai and Director Emeritus of the Jaffe Food Allergy Institute. He continues to direct his NIH-funded translational research activities and to see patients in clinical practice. Dr. Sampson leads both scientific and medical efforts overseeing DBV’s research team, pursuing potential new applications of Viaskin for the treatment of food allergies, while also supporting the Company’s clinical development teams. Dr. Sampson is past chair of the Section on Allergy & Immunology of the American Academy of Pediatrics and the past-president of the American Academy of Allergy, Asthma and Immunology. He received his M.D. from the State University of New York at Buffalo School of Medicine and his allergy/immunology fellowship at Duke University.